SenesTech Q1 revenue $415K record, up 78% YoY; Evolve drives >50% of sales

SenesTech, Inc.

2024-Q1 EPS reported -$0.36 revenue$415,000

Q1 2024 revenue $415,000, up 78% from $233,000 in Q1 2023; record quarterly revenue.
Net loss narrowed to $1.8M from $2.0M; adjusted EBITDA loss $1.7M vs $1.8M.
Evolve soft bait accounted for >50% of Q1 revenue; became biggest-selling product.
Launched Evolve Mouse in May 2024; extended distribution to Amazon, rep groups, 4,500 retail locations.
Cash at March 31, 2024 was $3.6M; New York City Council proposed deploying EPA-approved rat birth control.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

SenesTech, Inc. reported first quarter ended March 31, 2024 results: revenue $415,000, net income $1.8 million.

Period: first quarter ended March 31, 2024
Revenue: $415,000
Net income: $1.8 million
Result: reported results

Exact text from the filing

EPA-registered Rat Birth Control ® products today announced financial results for the first quarter of 2024. Recent Highlights • Record quarterly revenues during Q1 2024 of $415,000, an increase of 78% compared to Q1 2023. • EvolveTM, formulated especially for the control of rat fertility and launched at the beginning of the year, has quickly become the

View on SEC.gov

1052 earnings releases filed in the last 30 days. Browse all earnings releases →

SenesTech, Inc. filing history →

Source: SEC EDGAR

accession 0001628280-24-022205

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.